IHE publishes today the first sub-report in a report series on cancer care and access to cancer drugs in Asia-Pacific.
This report describes the disease burden of cancer. It shows that cancer patient numbers have been growing steadily in recent years along with the incoming silver tsunami. While more and more patients survive cancer in high-income markets (e.g., Australia and Japan), patient outcomes in middle-income markets are at best stagnating (e.g., China and India).
The burden of cancer in Asia-Pacific
IHE Report 2021:3c, IHE: Lund, Sweden